Ondansetron
DefinitionThis section has been translated automatically.
Pharmacodynamics (Effect)This section has been translated automatically.
IndicationThis section has been translated automatically.
Limited indicationThis section has been translated automatically.
Pregnancy/nursing periodThis section has been translated automatically.
Dosage and method of useThis section has been translated automatically.
Chemotherapy: 8 mg slowly i.v. or as a short infusion 15 min. before administration of the chemotherapeutic agent, then continuous infusion of 1 mg/hour over 24 hrs. or 8 mg p.o. 3 times/day.
Nephrogenic pruritus: 2-3 times/day 8 mg p.o.
Children > 2 yrs: Immediately before chemotherapy 5 mg/m2KO slowly i.v. over 15 minutes. Followed by oral administration of 4 mg every 12 hours (morning and evening) for 5 days.
Undesirable effectsThis section has been translated automatically.
Cutaneous adverse reactions: Rare hypersensitivity reactions, occasionally anaphylactoid reactions. Mild exanthematous skin lesions. Local reactions at the infusion site. In urticaria patients, application of the active substance may induce an episode.
Extracutaneous UAWs: Minor to moderate headache, constipation of mild or moderate severity, eye dryness. Occasionally flu-like symptoms with fever and chills.